Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BRBR stock price vs EW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EW's multiple
Needs EW P/E.
Implied fair value · at BRBR's multiple
Needs BRBR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BellRing Brands, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
EDWARDS LIFESCIENCES CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HERBALIFE LTD.
BRBR vs HLF
Simply Good Foods Co
BRBR vs SMPL
HORMEL FOODS CORP /DE/
BRBR vs HRL
Post Holdings, Inc.
BRBR vs POST
GENERAL MILLS INC
BRBR vs GIS
ABBOTT LABORATORIES
BRBR vs ABT
JOHNSON & JOHNSON
BRBR vs JNJ
Medtronic plc
BRBR vs MDT
BOSTON SCIENTIFIC CORP
BRBR vs BSX
BAXTER INTERNATIONAL INC
BRBR vs BAX
DENTSPLY SIRONA Inc.
BRBR vs XRAY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BRBR can sustain its 16.1% revenue growth while improving margins closer to EW levels, then BRBR looks attractive because the stock trades at 8.3x P/E and 0.7x P/S versus EW’s much richer multiples; if not, the current price may already reflect its weaker margin profile.
BRBR trades at a deep discount to EW on both earnings and sales multiples, with 8.3x P/E versus 51.6x for EW and 0.7x P/S versus 9.0x for EW. Despite that gap, the market is also valuing BRBR close to its own historical trading band, suggesting the stock is cheap relative to EW but not obviously dislocated versus its own history.
Supporting Metrics
